Most Recent
Apple will bring a “full-bodied” opposition to a bid to expand a class action over the running of its App Store, after a judge found the tech company engaged in anti-competitive conduct in the app marketplace last year.
Construction PRO
A developer linked to Keystone Asset Management has failed to persuade the Full Federal Court to exempt three family trusts from a $158 million freezing order.
Mayne Pharma cannot access invoices from Cosette’s solicitors at Corrs Chambers Westgarth, with a judge saying he was not hopeful that they would help to resolve a costs fight related to litigation over their collapsed $672 million merger.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Lander & Rogers has nabbed a finance partner from Corrs Chambers & Westgarth, who says his clients have been enthusiastic about his shift to a somewhat smaller firm.
Construction PRO
AkzoNobel has lost its bid to add new expert evidence after the conclusion of trial in a dispute with Inpex over allegedly defective anti-corrosive coating used on the $45 billion Ichthys natural gas project.
A judge has approved amendments to a shareholder class action against iSignthis and auditor Grant Thornton, over the opposition of the fintech firm, which argued the changes would amount to an abuse of process.
Boral's former CEO Zlatko Tordorcevski and ex-CFO Tino La Spina have been granted discovery as they mull possible claims against their former employer for curbing their long-term incentive entitlements when they left in 2022.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.